Navigation Links
Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
Date:10/5/2009

CHENGDU, China, Oct. 5 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co. Inc. (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today declared a quarterly cash dividend to be paid to its common stock shareholders. The dividend of $0.025 will be paid to shareholders of record as of October 30, 2009, with the actual distribution occurring on or about December 10, 2009.

In addition, Tianyin is now eligible to become an S-3 filer which is reserved for companies on a listed exchange that have filed all required reports on a timely basis during the past twelve months. This allows automatic updating of disclosure requirements with the 10-K or 10-Q filings and significantly reduces the costs and resource burdens on the company associated with filing post-effective amendments to the registration statement.

Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, commented, "We appreciate the continued support of our shareholders and believe that our strategy of providing a current return and potential capital appreciation resonates well with investors who are looking for growth and income. In addition, this S-3 eligibility will save the company money and resources to meet its filing requirements."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts during the presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.


    For more information, please contact:

    For the Company:
    Allen Tang, Ph.D., MBA, Assistant to the CEO in China
    Tel: +86-158-2122-5642
    Email: Allen.y.tang@gmail.com

    Investors:
    Mr. Matthew Hayden, HC International
    Tel: +1-561-245-5155
    Email: matt.hayden@hcinternational.net
    Web: http://www.hcinternational.net

SOURCE Tianyin Pharmaceutical Co. Inc.


'/>"/>
SOURCE Tianyin Pharmaceutical Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials ... combine to progress molecular radiotherapy imaging. In molecular ... to accurately quantify the radiation absorbed by those patients undergoing ... of this radiotherapy treatment has been available — that is, ... ...
(Date:7/5/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade cell and tissue hypothermic storage ... that it has reached an agreement with WAVI Holding ... modify its existing credit facility effective June 30, 2017. ... to exchange its existing $4.25 million credit facility, including ...
(Date:6/30/2017)... (AVACEN) announced the publication of new research in the peer-reviewed Fibromyalgia ... AVACEN Treatment Method to significantly reduce the widespread pain symptom ... ... ... to 400 million people worldwide according to The National Fibromyalgia Association. ...
Breaking Medicine Technology:
(Date:7/21/2017)... Norwalk, Connecticut (PRWEB) , ... July 21, 2017 , ... ... data from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in ... quarter of 2017, and up 15% from the 20 announced deals in the year-ago ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... ... ... West Dermatology is pleased to announce the newest addition to their Fresno, ... will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing with ... more. She graduated from the University of Florida College of Medicine Physician Assistant Program ...
(Date:7/20/2017)... ... , ... TransPixel Volume 2 is a set of transitions that create a ... isolates horizontal and vertical lines of pixels and sorts their pixels by darkness, brightness, ... and can be changed using a drop-down menu. Create amazing and artistic transitions using ...
(Date:7/20/2017)... ... 2017 , ... Coats Rose, P.C. , a business ... expansion to the Midwest with the establishment of the firm’s new Cincinnati office. ... of counsels, John Peck and Robert Bruns, will establish and anchor Coats Rose’s ...
Breaking Medicine News(10 mins):